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Abstract
Background For imatinib, a relationship between systemic
exposure and clinical outcome has been suggested.
Importantly, imatinib concentrations are not stable and
decrease over time, for which several mechanisms have
been suggested. In this study, we investigated if a decrease
in alpha-1 acid glycoprotein (AGP) is the main cause of the
lowering in imatinib exposure over time.
Methods We prospectively measured imatinib trough
concentration (Cmin) values in 28 patients with gastroin-
testinal stromal tumours, at 1, 3 and 12 months after the
start of imatinib treatment. At the same time points, AGP
levels were measured.
Results Overall, imatinib Cmin and AGP levels were cor-
related (r2 = 0.656; P\ 0.001). However, AGP levels did
not fluctuate significantly over time, nor did the change in
AGP levels correlate with the change in the imatinib Cmin.
Conclusion We showed that systemic AGP levels are not
likely to be a key player in the decrease in systemic ima-
tinib exposure over time. As long as intra-individual
changes in imatinib exposure remain unexplained,
researchers should standardize the sampling times for
imatinib in order to be able to assess the clinical applica-
bility of therapeutic drug monitoring.
Key Points
The decrease in systemic imatinib exposure during
the first months of treatment is not likely to be
caused by increased clearance due to fluctuations in
alpha-1 acid glycoprotein levels.
Since systemic imatinib exposure varies over time,
pharmacokinetic sampling should be performed at
standardized time points.
1 Background
Imatinib is one of the first tyrosine kinase inhibitors (TKIs)
for which therapeutic drug monitoring (TDM) is deemed
suitable in the treatment of both chronic myeloid leukaemia
(CML) and gastrointestinal stromal tumours (GISTs). In
CML, higher imatinib exposure has been found in patients
with a treatment response [1–4], and imatinib trough con-
centration (Cmin) values above 1000 ng/mL have been
found to be predictive of higher response rates [1, 2]. For
GIST, the target imatinib Cmin has been established in a
phase II study, in which patients with an imatinib Cmin in
the lowest quartile (i.e. below 1100 ng/mL) had signifi-
cantly worse progression-free survival (PFS), and it was
suggested that this concentration should serve as a target
Cmin [5]. Studies conducted in the context of routine care
have shown that more than half of imatinib-treated patients
do not reach that Cmin [6–8]. In these studies performed in
daily practice, the Cmin was measured more than 3 months
after the start of treatment, whereas in the study describing
the threshold of 1100 ng/mL, the imatinib Cmin was
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established after 4 weeks of treatment. Meanwhile, it has
been shown that imatinib clearance increases—and sys-
temic concentrations therefore decrease—during the first
3 months of treatment [9, 10]. Hence, it could be expected
upfront that an even larger proportion of patients than the
25 % in the phase II study would have a Cmin below
1100 ng/mL when it was determined later than 3 months
after the start of treatment, and doubts have been raised as
to whether this threshold set at a time when systemic
exposure has not yet stabilized is indeed the appropriate
target imatinib Cmin in patients with GIST [11]. Accord-
ingly, in one of the more recent retrospective studies in
GIST patients, a threshold of 760 ng/mL led to better
prediction of the outcome [8]. In the same study popula-
tion, however, the median PFS was longer for patients with
a Cmin[1100 ng/mL than for those with a Cmin[760 ng/
mL (67 versus 56 months) [8].
Several mechanisms have been suggested to account for
the reduction in systemic imatinib concentrations over
time, the first being decreased absorption [9]. Alternatively,
Chatelut et al. [12] proposed that systemic imatinib expo-
sure decreases because of increased clearance rather than
because of decreased absorption. As imatinib is predomi-
nantly bound to the acute-phase protein alpha-1 acid gly-
coprotein (AGP) [13–15], a reduction in AGP over time
would lead to less protein-bound imatinib and therefore a
larger proportion of free imatinib that could be metabolized
or excreted [12]. According to this theory, it is assumed
that a decrease in the tumour burden leads to a reduced
inflammatory syndrome, which in turn causes lowering of
AGP levels. The finding that changes in AGP levels over
time correlate well with changes in imatinib concentrations
seems to back this mechanism [16]. However, these data
were analysed in retrospect and, more importantly, they
were not collected in a structured manner, as imatinib
concentrations and AGP levels were measured at separate
time points. Additionally, AGP levels and imatinib con-
centrations were not assessed synchronously in that study.
To firmly establish the influence of AGP levels on blood
imatinib concentrations, this study aimed to prospectively
assess the correlation between imatinib Cmin values and
AGP levels.
2 Methods
2.1 Patients
Adult patients with GIST in whom commencement of
imatinib treatment was planned were eligible for inclusion
in this study. The exclusion criteria were prior imatinib
treatment within 3 months prior to the start of the study,
major surgery within 2 weeks prior to the start of the study,
use of potent cytochrome P450 (CYP) 3A inhibitors or
inducers, and inability to give or understand informed
consent. The study protocol was approved by the local
institutional review board (protocol number MEC13-203).
All procedures performed in this study were in accordance
with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki
Declaration and its later amendments or comparable ethical
standards. Written informed consent was obtained from all
individual participants included in the study.
2.2 Study Procedures
Pharmacokinetic sampling was performed at 1, 3 and
12 months after the start of imatinib treatment. At each
time point, two blood samples were collected in addition to
the standard-of-care blood draw at scheduled outpatient
visits. The first sample was collected in a glass tube con-
taining lithium heparin as an anticoagulant, and was used
to quantify the concentrations of imatinib and its main
metabolite, CGP74588. This sample was processed to
plasma within 30 minutes by centrifugation for 15 min at
25009g (4 C). Next, the plasma was transferred to
polypropylene tubes and stored at -70 C until the time of
analysis at the Laboratory of Translational Pharmacology,
Erasmus MC Cancer Institute (Rotterdam, the Nether-
lands). The methods used for quantification of imatinib and
CGP74588 concentrations have been described previously
[17]. The second sample was collected in a serum-sepa-
rating tube and processed to serum. Serum AGP levels
were measured using an immunoturbidimetric assay on a
Cobas Integra 800 (Roche Diagnostics GmbH, Mannheim,
Germany) in accordance with the instructions of the man-
ufacturer. Briefly, serum AGP was agglutinated with a
polyclonal goat-antihuman AGP antibody. The amount of
agglutination of the antigen–antibody complex was mea-
sured turbidimetrically.
2.3 Statistical Considerations
At least 24 patients had to be included to identify a rho
value of 0.55 in a two-sided test with alpha = 0.05 and
power = 0.8. Correlation was tested using Pearson’s cor-
relation, equality of two means was tested using t tests and
equality of more than two means was tested using one-way
analysis of variance (ANOVA). P values \0.05 were
considered statistically significant. Descriptive statistics
were performed using IBM SPSS Statistics version 21
software (SPSS, Chicago, IL, USA). All other statistical
analyses were performed using GraphPad Prism 5.0 soft-
ware (GraphPad Software, La Jolla, CA, USA).
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3 Results
3.1 Baseline
Between April 2013 and March 2015, 35 patients signed
informed consent and were included in the study. Four
patients were not evaluable because they stopped imatinib
treatment within 3 months and therefore did not provide
repetitive pharmacokinetic samples. In another three
patients, only one Cmin value was available because the
patients had taken imatinib prior to the other sampling time
points or because they had an imatinib concentration below
the limit of quantification (\20.0 ng/mL). The baseline
characteristics of the 28 evaluable patients are depicted in
Table 1. Eight of the evaluable patients stopped treatment
before the final sampling time point because of progressive
disease (n = 3), cessation of neoadjuvant treatment
(n = 4) or toxicity (n = 1).
3.2 AGP Levels and Imatinib Concentrations
A total of 73 imatinib trough concentration samples were
obtained. In 69 cases, a blood sample for measurement of
the AGP level was collected synchronically. The mean
values of AGP, imatinib and CGP74588 at each time point
are depicted in Table 2. At any of the three time points, the
AGP levels in the five patients treated in the adjuvant
setting did not differ significantly from those in the patients
treated in the neoadjuvant or palliative settings (Fig. 1a).
3.3 AGP Versus Imatinib
Overall, AGP levels were significantly correlated with
imatinib concentrations (r2 = 0.656; P\ 0.001; Fig. 2)
and with the sum of imatinib and CGP74588 concentra-
tions (r2 = 0.667; P\ 0.001). The correlation between
imatinib concentrations and AGP levels was less strong in
the 25 samples that were taken at the first time point after
30 days (r2 = 0.526; P\ 0.001; Fig. 3) in comparison
with the correlations assessed at the two later time points.
The absolute difference in AGP levels between time points
1 and 2 was also significantly correlated with the absolute
difference in imatinib concentrations between time points 1
and 2 (r2 = 0.381; P = 0.002) and between time points 1
and 3 (r2 = 0.355; P = 0.03). The relative differences in
AGP levels and imatinib concentrations between time
points were not significantly correlated. The geometric
mean AGP levels did not differ significantly between the
three time points (P = 0.141; Fig. 1b).
4 Discussion
In this prospective setting, imatinib pharmacokinetics were
closely correlated with systemic AGP levels when all
samples obtained at the three different time points were
considered together (r2 = 0.656; P\ 0.001). Although—
at first sight—this appeared to be in line with the hypoth-
esis that the increase in imatinib clearance is due to
reduced systemic AGP levels [14, 16], the differences in
AGP levels and imatinib Cmin values between the time
points were less strongly correlated. Moreover, the argu-
ment that AGP decreases during treatment and thereby
contributes to increased imatinib clearance over time [12]
did not seem to hold true, as we did not find substantial
reductions in AGP levels during treatment (P = 0.141;
Fig. 1). Patients treated in the adjuvant setting even had a
gradual increase in AGP levels, which contradicted the
theory that AGP levels are initially elevated because of an
inflammatory syndrome directly after tumour surgery and
decline over time when the surgery effects resolve [12].
Even though the decrease in imatinib concentrations was
Table 1 Baseline patient characteristics
Characteristic Patients, n = 28
Age at start
Years 69 (10)
Sex
Male 16 (57 %)
Female 12 (43 %)
WHO performance status
0 12 (43 %)
1 13 (46 %)
2 1 (4 %)
Unknown 2 (7 %)
c-KIT mutation
Wild type 5 (18 %)
Exon 9 6 (21 %)
Exon 11 12 (43 %)
Exon 13 3 (11 %)
Unknown 2 (7 %)
Treatment setting
Neoadjuvant 11 (39 %)
Adjuvant 5 (18 %)
Palliative 12 (43 %)
Dose at start
300 mg QD 1 (4 %)
400 mg QD 26 (93 %)
800 mg QD 1 (4 %)
All values are presented as n (%) or as mean (standard deviation)
c-KIT KIT proto-oncogene receptor tyrosine kinase, QD once daily,
WHO World Health Organization
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not as large as those published previously, the implication
of our current findings is that the role of systemic AGP
levels in the reduced systemic imatinib exposure over time
is relatively small and that other factors, e.g. reduced
bioavailability, likely have larger influences on systemic
exposure. Still, AGP might seriously interfere with ima-
tinib exposure in vivo, as extravascular AGP affects ima-
tinib pharmacokinetics beyond the systemic circulation
[15], and preclinical research has shown that the
Table 2 Analyses of the samples obtained at the different time points
Time point 1, n = 25 Time point 2, n = 25 Time point 3, n = 19 Total, n = 69
Actual time since start of imatinib [days]a 30 (3) 97 (30) 364 (20)
AGP level [g/L]b 0.97 (0.85–1.10) 0.81 (0.69–0.94) 0.89 (0.78–1.00) 0.89 (0.82–0.96)
Imatinib concentration [ng/mL]b 1457 (1155–1838) 1305 (1001–1702) 1193 (967–1472) 1325 (1158–1516)
CGP74588 concentration [ng/mL]b 308 (247–384) 265 (205–343) 231 (179–299) 270 (235–309)
Imatinib ? CGP74588 concentration [ng/mL]b 1777 (1420–2224) 1578 (1217–2047) 1439 (1165–1777) 1606 (1407–1833)
Correlation between imatinib and AGPc 0.526 (P\ 0.001) 0.839 (P\ 0.001) 0.411 (P = 0.003) 0.656 (P\ 0.001)
The three time points are the times at which sampling was scheduled according to the protocol, i.e. 30 days, 90 days and 365 days after the start
of treatment
AGP alpha-1 acid glycoprotein
a Units of time are presented as mean (standard deviation)
b Values are presented as geometric mean (95 % confidence interval)
c Correlations are depicted as r2 (P value)
Fig. 1 a Geometric mean levels of alpha-1 acid glycoprotein (AGP)
at 30 days (white bars), 90 days (striped bars) and 365 days (dark
grey bars) from the start of treatment in each treatment setting.
b Geometric mean trough concentrations of imatinib (black bars) and
AGP (white bars) at each time point. The error bars represent the
95 % confidence intervals
Fig. 2 Correlation between imatinib concentrations and alpha-1 acid
glycoprotein (AGP) levels in all samples (n = 69)
Fig. 3 Correlation between imatinib concentrations and alpha-1 acid
glycoprotein (AGP) levels at 30 days (n = 25)
308 S. Bins et al.
pharmacodynamic effects of imatinib are reduced in the
presence of AGP [18–20]. Nonetheless, it remains ques-
tionable whether these extravascular effects can be used to
determine the optimal dose for individual patients.
Unfortunately, the available evidence for individualized
imatinib dosing in GIST patients is currently not robust,
hampering assessment of the clinical relevance of TDM in
GIST. Imatinib Cmin values measured at different time
points during treatment have previously been related to the
clinical outcome [5, 8]. Also, as mentioned previously,
because of the decrease in systemic imatinib concentrations
over time, target Cmin values after 1 month cannot be
extrapolated into a dosing algorithm for the entire treat-
ment period. Although it has been proposed that TDM be
performed only after imatinib pharmacokinetics have sta-
bilized after 3 months of treatment [11], whether or not an
individual with GIST receives the proper treatment and
dose would ideally become visible much earlier during
treatment. For example, by using fludeoxyglucose (18F)
[18F-FDG] positron emission tomography [PET] as early as
a few days after the start of treatment, it is possible to know
whether or not a GIST patient is responding to treatment
[21]. Either way, TDM in imatinib treatment can reach its
full potential only when sampling times are standardized
between research groups [22]. The sampling schedule
employed in the current study could serve as a blueprint for
larger studies because it incorporated Cmin values at
1 month and at later time points, enabling assessment of
long-term pharmacokinetic targets, which could subse-
quently be compared with the established target at
1 month. Alternatively, long-term pharmacokinetic targets
could be derived from the target Cmin at 1 month, using a
formula that corrects for the parameters that contribute to
the decrease in imatinib exposure. However, as the bio-
logical mechanism of this decreased exposure seems to be
complex and multifactorial, the latter option to determine
long-term pharmacokinetic targets is not likely to be
computed soon. In parallel, other challenges in making
TDM clinically usable will be to integrate the dosing range
(300–800 mg daily) and the possible options in the case of
insufficient concentrations (dose escalation or a treatment
switch), but these are secondary to standardization of the
sampling time points. Last, but certainly not least, it
remains to be proven that imatinib TDM in GIST really
translates into a better outcome in terms of either less
toxicity or better anti-tumour effects.
5 Conclusion
We found that systemic AGP levels are not likely to be a
key player in the decrease of systemic imatinib exposure
over time. We believe that TDM is a very potent tool to
improve personalized imatinib treatment, but it can flourish
only if researchers ensure that their results are obtained in a
standardized way.
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